News
5/4/2013

UPF, CRG, IMIM: New treatment identified for fragile X syndrome

UPF, CRG, IMIM: New treatment identified for fragile X syndrome


News from the UPF and the IMIM


Researchers from the Laboratory of Neuropharmacology at the UPF demonstrate that the endocannabinoid system is a new therapeutic target for treating fragile X syndrome (FXS), a rare disease which is the most common hereditary cause of intellectual disability. Their work has been published in Nature Medicine.

The authors, which also include scientists at the IMIM and the CRG, have observed that blocking cannabinoid receptors CB1 normalizes cognitive deficits, lack of sensitivity to painful stimuli and susceptibility to seizures that appear in the mouse model for FXS.

More information:

UPF press release (in English)

UPF press release (in Catalan)

 

Reference:

Busquets-Garcia A., Gomis-González M., Guegan T., Agustín-Pavón C., Pastor A., Mato S, Pérez-Samartín A., Matute C., de la Torre R., Dierssen M., Maldonado R., Ozaita A. "Targeting the endocannabinoid system in the treatment of fragile X syndrome". Nature Medicine doi: 10.1038/nm.3127. 31/3/2013.